BioSpace News Archive

The Coalition for Epidemic Preparedness Innovations and Moderna, Inc. have entered into a strategic partnership that will harness Moderna’s mRNA platform to accelerate the development of vaccines against viral disease outbreaks that threaten global health.

Foresee Pharmaceuticals, announced that the company will be presenting at the American Heart Association 2023 Annual Meeting taking place in Philadelphia, PA, from November 11-13, 2023.

Calibre Scientific is pleased to announce the acquisition of C.P.S. Analitica S.r.l., an Italian provider of chromatography consumables for the pharmaceutical, biotech, life sciences, academic, food & beverage, environmental and chemical industries.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Healiva SA and C4U Corporation are pleased to announce that they have entered into a strategic alliance agreement regarding the development of CRISPR-Cas3 derived therapeutic solutions for Epidermolysis Bullosa, also known as “butterfly children”.

Enterome announced that it received a €3 million investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program®.

ArriVent Biopharma, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for furmonertinib for the treatment of patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

Turnstone Biologics Corp. announced the addition of Jeffrey S. Weber, M.D., Ph.D., to its Scientific Advisory Board.

Vizient announced it has completed its acquisition of PrefTech OR, a next-generation, cloud-based preference card management software that helps healthcare providers optimize their operating rooms to increase workflow efficiency, lower costs and improve patient care.

MannKind Corporation announced a new patent issued by the United States Patent and Trademark Office covering clofazimine inhalation suspension, which is under development for the potential treatment of nontuberculous mycobacterial lung disease.